Report: Creating a sustainable business model for cell and gene therapies
By AmerisourceBergen
The path to success for new cell and gene therapies (CGTs) is full of challenges. And yet the pressure on therapy manufacturers to deliver results is only growing. To examine how to make development and commercialization of these therapies more sustainable, Economist Impact facilitated a roundtable discussion, supported by AmerisourceBergen, as part of the Cell and Gene Therapy Summit 2023.
Summit Report
The Economist’s inaugural event on CGTs convened leaders and policy decision-makers to accelerate access to transformative products
Access the post event report to discover the key takeaways from over 20 sessions about how healthcare systems and policies need to evolve before therapies can become mainstream.
Topics:
Cell and gene therapy
